The Biden administration on Friday (March 4) will unveil a final rule that aims to bring manufacturing of critical supplies, including drugs, back to the United States, but key drug industry groups and a leading health policy organization believe the rule’s provisions will have little to no effect on the pharmaceutical industry as they don’t provide incentives for drug makers. Over the next seven years, the regulation will increase the amount of U.S.-made ingredients a drug must contain to be...